Novus Biologicals, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novus Biologicals, LLC
Janssen reported treatment altering Phase III data at ASCO 2017 for a new Zytiga combination targeting hormone-naïve metastatic prostate cancer patients – but the triple regimen's relevance might be short-lived as momentum builds in the late-stage pipeline.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
- Research, Analytical Equipment & Supplies